On April 3, 2018 OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, reported it will host a Research Reception at the 2018 American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, OncoSec Medical, APR 3, 2018, View Source [SID1234525161]). The reception, for which registration is required, will be held on Sunday, April 15, 2018 at 6:00 p.m. CT at the JW Marriott in Chicago, IL.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The OncoSec Research Reception will feature the following presentations:
OMS-140 Protocol; Review of Intratumoral IL-12 Data in TNBC Presented at AACR (Free AACR Whitepaper)
Pamela Munster, MD, UCSF Helen Diller Family Comprehensive Cancer Center
OMS-141 Protocol; Upcoming PD-1 Combination Clinical Trial in TNBC
Melinda Telli, MD, Stanford University Medical Center
Melanoma Data Update: OMS-100 & OMS-102 Combination Study
Alain Algazi, MD, UCSF Helen Diller Family Comprehensive Cancer Center
PISCES/KEYNOTE-695 Operational Update
Sharron Gargosky, PhD, Chief Clinical and Regulatory Officer, OncoSec
Attendees will also have the opportunity to view the TNBC data featured as an oral poster at AACR (Free AACR Whitepaper) and ask questions of the lead author. All speakers will be available for questions. Space is limited. For those interested in attending this event in person, please contact [email protected].
An archived version of the presentation will be available for 90 days on OncoSec’s website: www.oncosec.com.